Entera Bio Ltd
NASDAQ:ENTX
Entera Bio Ltd
NASDAQ:ENTX
Price:
2.708 USD
7.89%
Market Closed
Updated:
May 15, 2024
Entera Bio Ltd
Research & Development
|
Entera Bio Ltd
Research & Development Peer Comparison
Comparables:
CLGN
KMDA
B
BLRX
URGN
B
BONS
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Research & Development
-$4.5m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Research & Development
-$10.5m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Research & Development
-$13.3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
0%
|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Research & Development
-$11.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
0%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Research & Development
-$45.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Research & Development
-₪19.6m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-15%
|
See Also
What is Entera Bio Ltd's Research & Development?
Research & Development
-4.5m
USD
-4.5m
USD
Based on the financial report for Dec 31, 2023, Entera Bio Ltd's Research & Development amounts to -4.5m USD.
What is Entera Bio Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
12%
12%
Over the last year, the Research & Development growth was 23%. The average annual Research & Development growth rates for Entera Bio Ltd have been 11% over the past three years , 12% over the past five years .
You don't have any saved screeners yet
